CAMBRIDGE, Mass, January 5, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that Daniel Getts, Ph.D., CEO of Myeloid, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023, in San Francisco, CA. The company is scheduled to present on Thursday, January 12, 2023, at […]
CAMBRIDGE, Mass, Nov. 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that the Company will participate at the Jefferies London Healthcare Conference taking place from November 15-17, 2022 in London. Company management will meet one-on-one with investors during the conference. About Myeloid Therapeutics Myeloid Therapeutics is a clinical […]
Myeloid Therapeutics Presents Update On Myeloid Cell Programming Technologies, Including Non-Human Primate Proof-Of-Concept Data Delivering in vivo mRNA TROP-2 Targeting CAR (MT-302) at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting -New preclinical data on lead in vivo programming program, MT-302, demonstrates strong expression and favorable safety in myeloid cells following a single administration […]
Daniel Getts, CEO of Myeloid Therapeutics, wants to cure cancer. – – Daniel Getts, CEO of Myeloid Therapeutics, wants to cure cancer. He admits it’s a legitimately bold thing to say, but he has a strong belief that he will make an impact someday. When he walks into his office in Cambridge, Mass., he is […]
Myeloid Therapeutics Appoints Leading Immunologist, Cell & Gene Therapy Expert Bruce McCreedy, Ph.D.
Dr. McCreedy brings decades of executive-level biopharmaceutical experience to advance research and development of novel myeloid-targeting therapies. CAMBRIDGE, Mass., May 4, 2021 /PRNewswire/ — Myeloid Therapeutics, Inc., a clinical-stage immunology company that is combining RNA insights with new technology to develop powerful cancer therapies, today announced that industry veteran Bruce McCreedy, Ph.D., has joined the […]